The Journey of Empagliflozin

Empagliflozin is well absorbed orally with bioavailability of
approximately 78%. Peak plasma concentrations are reached within 1.5 hours after oral administration.
Food modestly delays absorption but does not reduce overall bioavailability, so the drug may be
taken with or without food. Empagliflozin tablets are available in 10 mg and 25 mg strengths.
The drug is not a substrate for intestinal efflux transporters to a clinically significant degree,
enabling consistent absorption across a range of patient populations. Studies in patients with
varying degrees of renal impairment show that absorption is unchanged by renal function —
pharmacodynamic effects (glycosuria) are reduced in severe renal impairment because less glucose
is filtered, not because absorption is impaired.

Empagliflozin distributes throughout the body with a volume of
distribution of approximately 73 L. Plasma protein binding is approximately 86%, predominantly to
albumin. The drug selectively targets the kidney's proximal tubule luminal membrane, where SGLT2 is
expressed, achieving the pharmacological effect at relatively low free plasma concentrations. Unlike
systemic glucose-lowering mechanisms, empagliflozin's action at the proximal tubule does not require
entering cells — it inhibits a transporter on the luminal surface accessible from tubular fluid.
Tissue distribution beyond plasma and interstitial fluid is limited. The drug crosses the placenta
and is present in breast milk in animal studies, leading to contraindication in pregnancy and
lactation.

SGLT2 (sodium-glucose cotransporter 2, SLC5A2) is expressed almost
exclusively in the S1 and S2 segments of the proximal convoluted tubule. It couples the electrochemical
gradient of sodium (maintained by basolateral Na/K-ATPase) to glucose transport, normally reabsorbing
approximately 90% of the 160-180 g of glucose filtered daily by the glomerulus (with SGLT1 handling
most of the remaining 10%). Empagliflozin competitively and reversibly inhibits SGLT2 with high
selectivity (SGLT2:SGLT1 selectivity ratio >2,500:1), blocking glucose-sodium cotransport. The
resulting glucosuria (60-90 g/day) creates a caloric deficit equivalent to 240-360 kcal/day,
driving weight loss. Sodium excretion alongside glucose reduces extracellular volume, blood pressure,
and — critically — reduces intraglomerular pressure (by restoring tubuloglomerular feedback through
increased sodium delivery to the macula densa), explaining the nephroprotective effects seen in
the EMPA-REG OUTCOME and EMPA-KIDNEY trials.

Empagliflozin undergoes glucuronidation as the primary metabolic
pathway, forming three pharmacologically inactive glucuronide metabolites (2-O-, 3-O-, and 6-O-
glucuronides) catalyzed primarily by UGT2B7, UGT1A3, UGT1A8, and UGT1A9. CYP450 enzyme-mediated
oxidative metabolism contributes minimally (<10% of the dose). This glucuronidation-dominant metabolism
profile means empagliflozin has very few clinically relevant CYP-based drug interactions — it is not
metabolized by CYP3A4, CYP2D6, or CYP2C9, and is not a clinically significant inhibitor or inducer
of CYP enzymes. The absence of meaningful CYP interactions makes empagliflozin pharmacokinetically
favorable in polypharmacy patients. Dose adjustments for hepatic impairment are not required except
in severe hepatic failure where UGT activity may be reduced.

Empagliflozin is excreted primarily in feces (41.2%) and urine
(54.4%). Approximately 28% of the dose is recovered as unchanged drug in feces and approximately
18% in urine. The remainder is excreted as glucuronide metabolites. The terminal elimination half-life
is approximately 12.4 hours, supporting once-daily dosing. Renal clearance contributes to elimination
but is reduced in renal impairment without necessitating dose adjustment (though the glycemic efficacy
diminishes). Empagliflozin is not removed efficiently by hemodialysis due to high protein binding.
In severe renal impairment (eGFR <30), use is generally not recommended for glycemic control, though
cardioprotective benefits persist at lower eGFR levels per updated guidelines.

Empagliflozin demonstrated unprecedented cardiovascular benefits in
the EMPA-REG OUTCOME trial — 38% reduction in cardiovascular death in patients with type 2 diabetes
and established cardiovascular disease. The EMPA-KIDNEY trial showed 28% reduction in kidney disease
progression or CV death across a broad range of CKD patients. Adverse effects include genital mycotic
infections (glucosuria promotes Candida and bacterial growth), euglycemic diabetic ketoacidosis (rare
but dangerous, especially with fasting, surgery, or low carbohydrate intake), and volume depletion.
Fournier's gangrene (necrotizing fasciitis of the perineum), though very rare, led to an FDA boxed
warning. The drug is now approved for heart failure with both reduced and preserved ejection fraction.